Patents by Inventor Hélène BARIBAULT

Hélène BARIBAULT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WNT SURROGATE MOLECULES AND USES THEREOF
    Publication number: 20240141049
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: May 2, 2024
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Claudia Yvonne JANDA, Tristan William FOWLER, Helene BARIBAULT, Kuo-Pao LAI, Liqin XIE, Randall J. BREZSKI, Chenggang LU
  • LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
    Publication number: 20230374090
    Abstract: The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 23, 2023
    Applicant: Surrozen Operating, Inc.
    Inventors: Yang LI, Zhengjian ZHANG, Randall J. BREZSKI, Leonard PRESTA, Thomas LOPEZ, Hui CHEN, Helene BARIBAULT, Wen-Chen YEH, Shengjiang TU
  • WNT surrogate molecules and uses thereof
    Patent number: 11773171
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 3, 2023
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Claudia Yvonne Janda, Tristan William Fowler, Helene Baribault, Kuo-Pao Lai, Liqin Xie, Randall J. Brezski, Chenggang Lu
  • Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
    Patent number: 11718619
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: August 8, 2023
    Assignee: Ardelyx, Inc.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS
    Publication number: 20230139597
    Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
    Type: Application
    Filed: July 6, 2022
    Publication date: May 4, 2023
    Applicant: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS
    Publication number: 20220195053
    Abstract: The present invention provides methods of treating gastrointestinal disorders with modulators of the WNT signaling pathway. Also provided are methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 23, 2022
    Applicant: Surrozen Operating Inc.
    Inventors: Yang LI, Chenggang LU, Hélène BARIBAULT, Wen-Chen YEH, Liqin XIE, I-Chieh WANG, Weixu MENG
  • TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES
    Publication number: 20210380678
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues.
    Type: Application
    Filed: July 9, 2019
    Publication date: December 9, 2021
    Inventors: Zhengjian ZHANG, Yang LI, Wen-Chen YEH, Tom Zhiye YUAN, Helene BARIBAULT, Kuo-Pao LAI
  • ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS
    Publication number: 20210300927
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Application
    Filed: April 7, 2021
    Publication date: September 30, 2021
    Applicant: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
    Patent number: 11091482
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: August 17, 2021
    Assignee: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS
    Publication number: 20210017177
    Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
    Type: Application
    Filed: August 11, 2020
    Publication date: January 21, 2021
    Applicant: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Hormone receptor modulators for treating metabolic conditions and disorders
    Patent number: 10793568
    Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 6, 2020
    Assignee: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • WNT SURROGATE MOLECULES AND USES THEREOF
    Publication number: 20200308287
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: December 19, 2018
    Publication date: October 1, 2020
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Claudia Yvonne JANDA, Tristan William FOWLER, Helene BARIBAULT, Kuo-Pao LAI, Liqin XIE, Randall J. BREZSKI, Chenggang LU
  • ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS
    Publication number: 20190308973
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Application
    Filed: August 23, 2017
    Publication date: October 10, 2019
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS
    Publication number: 20190233420
    Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
    Type: Application
    Filed: August 23, 2017
    Publication date: August 1, 2019
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • METHOD OF IDENTIFYING COMPOUNDS THAT SPECIFICALLY MODULATE THE INTERACTION OF FGFR1 AND BETA KLOTHO
    Publication number: 20140189893
    Abstract: Methods of identifying compounds that specifically modulate the interaction of FGFR1 and ?-Klotho are disclosed. Identified compounds can be useful in treating metabolic diseases and disorders that involve the interaction of FGFR1 and ?-Klotho. In various embodiments the metabolic disease or disorder is diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: February 20, 2012
    Publication date: July 3, 2014
    Applicant: AMGEN INC.
    Inventors: Yang Li, Xinle Wu, Hongfei Ge, Helene Baribault, Bryan Lemon, Jackie Z. Sheng, Steven Vonderfecht, Jennifer Veronica Weiszmann, Jonitha Gardner, Grace Ki Jeong Lee
  • Transgenic mice containing retinoid X receptor interacting protein gene disruptions
    Publication number: 20060137031
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in the LXRB gene. Such transgenic mice are useful as models for disease, such as diabetes. The present invention is also directed to identifying agents that modulate LXRB gene function, and as potential treatments for various disease states and disease conditions, including diabetes.
    Type: Application
    Filed: February 13, 2006
    Publication date: June 22, 2006
    Inventors: Keith Allen, Catherine Guenther, Russell Phillips, Qin Zhang, Helene Baribault
  • Transgenic mice containing alpha-endosulfine gene disruptions
    Publication number: 20020137203
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a alpha-endosulfine gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions. The present invention also relates to diabetes and diabetic condition, as it demonstrates the role of the alpha-endosulfine in diabetes and diabetic conditions. The present invention further relates to weight gain and weight related conditions, such as obesity, and demonstrates the role of the alpha-endosulfine in weight gain and weight related conditions, such as obesity.
    Type: Application
    Filed: December 13, 2001
    Publication date: September 26, 2002
    Inventors: Michael V. Wiles, Helene Baribault, Qin Zhang
  • Transgenic mice containing retinoid X receptor interacting protein gene disruptions
    Publication number: 20020116731
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in the LXRB gene. Such transgenic mice are useful as models for disease, such as diabetes. The present invention is also directed to identifying agents that modulate LXRB gene function, and as potential treatments for various disease states and disease conditions, including diabetes.
    Type: Application
    Filed: December 10, 2001
    Publication date: August 22, 2002
    Inventors: Keith D. Allen, Catherine Guenther, Russell Phillips, Qin Zhang, Helene Baribault